Premium
Early switch to second‐line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular response
Author(s) -
KlilDrori Adi J.,
Yin Hui,
Azoulay Laurent,
Harnois Michaël,
Gratton MichelOlivier,
Del Corpo Alexa,
Olney Harold J.,
Delage Robert,
Laneuville Pierre,
Mollica Luigina,
Busque Lambert,
Assouline Sarit E.
Publication year - 2017
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.24838
Subject(s) - medicine , hazard ratio , myeloid leukemia , tyrosine kinase inhibitor , oncology , adverse effect , confidence interval , cancer
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom